一、基本情況
張新科，女，博士，副高級職稱，碩士生導師；
推荐几个网赌网站新藥藥理研究所,藥學院新藥創制篩選平台工作。
Tel：0531-88382490；
E-mail: zhangxinke@sdu.edu.cn
二、學習經曆
2009/9-2012/6，山東大學，藥學院生物技術研究所，博士；
2006/9-2009/6，山東大學，藥學院藥劑所，碩士；
2002/9-2006/6，山東大學，藥學院，學士
三、工作經曆
副高：2017.09-至今推荐几个网赌网站新藥藥理研究所新藥篩選平台
訪問學者：2018.03-2019.09美國加州大學戴維斯分校
中級：2012.07-2017.08，推荐几个网赌网站新藥藥理研究所新藥篩選平台
四、研究方向
1.納米制劑遞送給藥
針對血管增生性疾病（腫瘤、糖尿病視網膜病變等），緻力于研究高效穿透血腦屏障或眼球屏障的納米靶向制劑。
2.蛋白多肽類研究
主要緻力于融合蛋白的表達、純化及活性研究；設計篩選多功能靶向穿膜肽使其用于血管增生性疾病的治療
3.外泌體的研究
對間充質幹細胞外泌體的産量、工程化及活性評價研究。
五、承擔的科研項目（縱向）
1.國家自然科學基金面上項目，神經元靶向的載藥細胞外囊泡的構建及對腦缺血再灌注神經元損傷的保護作用及機制研究，主持，立項日期，2023.01。
2.山東省自然科學基金面上項目，新型穿膜雙靶向肽TAT-AT7對神經膠質瘤的靶向治療作用及機制研究，立項日期，2021/01
3.山東省重點研發計劃，主動靶向肽A7介導的載TatPTD-内皮抑素基因殼聚糖納米載體治療眼部血管增生疾病的成藥性研究,立項日期，2016/09。
4.國家自然科學基金項目，雙修飾殼聚糖載TatPTD-内皮抑素基因納米粒靶向抑制眼底血管增生的研究，立項日期2014/01
六、承擔教學工作
藥理學實驗、臨床藥理學實驗
七、代表性學術論文
1.Wei Pan, Hongyuan Chen, Aijun Wang, Fengshan Wang,Xinke Zhang（通訊作者）. Challenges and strategies: Scalable and efficient production of mesenchymal stem cells-derived exosomes for cell-free therapy. Life Sciences. 2023, 319, 121524.
2.Longkun Wang, Chunqian Zhao, Lu Lu, Honglei Jiang, Fengshan Wang,Xinke Zhang（通訊作者）. Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle forTargeted Treatment of Triple-Negative Breast Cancer. International Journal of Molecular Sciences. 2023,24, 4646.
3.Shang Chen,Chenyan Ren,Yuan Ji,Dongke Liu,Xinke Zhang(通訊作者) ,Fengshan Wang.The Pharmacokinetics in Mice and Cell Uptake of Thymus Immunosuppressive Pentapeptide Using LC-MS/MS Analysis.Molecules,2022 ,27(13):4256.
4.Longkun Wang,Hongyuan Chen,Fengshan Wang,Xinke Zhang*(通訊作者). The development of peptide-drug conjugates (PDCs) strategies for paclitaxel. Expert Opin Drug Deliv. 2022,19(2):147-161.
5.Chunqian Zhao,Hongyuan Chen,Fengshan Wang,Xinke Zhang*(通訊作者). Amphiphilic self-assembly peptides: Rational strategies to design and delivery for drugs in biomedical applications. Colloids Surf B Biointerfaces,2021,208:112040.
6.Lin Zhao,Hongyuan Chen,Lu Lu, Chunqian Zhao, Christina V. Malichewe,Lei Wang,Xinke Zhang*(通訊作者),Xiuli Guo.Design and screening of a novel neuropilin-1 targeted penetrating peptide for anti-angiogenic therapy in glioma. Life Sciences, 2021,270,119113
7.Lin Zhao,Hongyuan Chen,Lu Lu,Lei Wang,Xinke Zhang*(通訊作者),Xiuli Guo. New insights into the role of co-receptor neuropilins in tumour angiogenesis and lymphangiogenesis and targeted therapy strategies.Journal of Drug Targeting. 2021,29(2):155-167
8.Lu Lu,Hongyuan Chen,Longkun Wang,Lin Zhao,Yanna Cheng,Aijun Wang,Fengshan Wang,Xinke Zhang*(通訊作者).A Dual Receptor Targeting- and BBB PenetratingPeptide Functionalized Polyethyleneimine Nanocomplex for Secretory Endostatin Gene Delivery to Malignant Glioma. International Journal of Nanomedicine, 2020, 15: 8875–8892.
9.Lu Lu,Chen Hongyuan,Hao Dake,Zhang Xinke*(通訊作者),Wang Fengshan. The functions and applications of A7R in anti- angiogenic therapy, imaging and drug delivery systems. Asian Journal of Pharmaceutical Sciences.2019,14(6):595-608
10.Xinke Zhang,Peng Li,Shaohua Guo,Shuqi Wang,Dasheng Liu.Quantitation ofβ-carboline and quercetin in alligator weed (Alternanthera philoxeroides (Mart.) Griseb.) by LC-MS/MS and evaluation of cardioprotective effects of the methanol extracts. Drug Discov Ther. 2018;12(6):341-346.
11.Zhang Xinke, Li Yan, Cheng Yanna, Tan Haining，Li Zhiwei, Qu Yi, Mu Guoying, Wang Fengshan.Tat PTD-endostatin: a novel anti-angiogenesis protein with ocular barrier permeability via eye-drops. BBA General Subjects,2015;1850(6):1140-9.
12.Zhang Xinke, Zhang Xue, Wang Fengshan.Intracellular transduction and potential of Tat PTD and its analogs: from basic drug delivery mechanism to application. Expert opinion on drug delivery, 9(4):457-72, 2012.
13.Zhang XinKe, Sun Ping, Bi Ru, Wang Jinping, Zhang Na, Huang GuiHua.Targeted delivery of levofloxacin-liposomes for the treatment of pulmonary inflammation. Journal of Drug Targeting, 17(5):399–407, 2009.
14.Li Pingli, Zhang Xinke, Cheng Yanna , Li Juan , Xiao Yuliang , Zhang Qian, Zong Aizhen, Zhong Chuanqing, Wang fengshan. Preparation and in vitro immunomodulatory effect of curdlan sulfate. Carbohydrate Polymers, 2014, 102: 852– 861
15.Li Juan,Cheng Yanna,Zhang Xinke,Zheng Lei,Han Zhen,Li Pingli,Xi-ao Yuliang,Zhang Qian,Wang Fengshan. The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide and its binding to TLR2.Cancer Lett.2013,337(2):237-47
